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Background: The survival rate of malignant tumors, and especially hepatocellular carcinoma (HCC), has not
improved primarily because of uncontrolled metastasis. In our previous studies, we have reported that Terminalia
catappa leaf extract (TCE) exerts antimetastasis effects on HCC cells. However, the molecular mechanisms of
urokinase-type plasminogen activator (u-PA) in HCC metastasis have not been thoroughly investigated, and remain
poorly understood.
Methods: The activities and protein levels of u-PA were determined by casein zymography and western blotting.
Transcriptional levels of u-PA were detected by real-time PCR and promoter assays.
Results: We found that treatment of Huh7 cells with TCE significantly reduced the activities, protein levels and
mRNA levels of u-PA. A chromatin immunoprecipitation (ChIP) assay showed that TCE inhibited the transcription
protein of nuclear factors SP-1 and NF-κB. TCE also did inhibit the effects of u-PA by reducing the phosphorylation
of ERK1/2 pathway.
Conclusions: These results show that u-PA expression may be a potent therapeutic target in the TCE-mediated
suppression of HCC metastasis.
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Hepatocellular carcinoma (HCC) is a common malignant
neoplasm in Asian countries, and is the fifth most com-
mon cancer and the third most common cause of cancer
mortality worldwide [1,2]. The survival rate of HCC in
Taiwan has not increased primarily because of undamped
tumor invasion and metastasis [3,4]. Cancer cells from
the primary tumor invade neighboring tissue through
the secretion of urokinase-type plasminogen activator
(u-PA). This degrades the basement membrane and
separates the intercellular matrix, penetrating the cir-
culation system and causing cancer cell invasion and
metastasis [5].* Correspondence: 170780@cch.org.tw; ysf@csmu.edu.tw
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reproduction in any medium, provided the orThe u-PA serine protease is secreted as a 53 KD zymo-
gen (pro-urokinase), and has 3 structural domains: the
growth factor domain, kringle domain and serine protease
domain [6-8]. The u-PA system includes 4 components:
u-PA, urokinase plasminogen activator receptor (u-PAR),
and plasminogen activator inhibitors (PAI)-1 and PAI-2. El-
evated expression levels of u-PA are correlated with tumor
malignancy [5,9]. In general, u-PA is involved in extra-
cellular matrix (ECM) degradation and the invasion and
metastasis of cancer cells by regulating the plasminogen/
plasmin system. Moreover, the u-PA bound to u-PAR en-
hances its blood plasminogen activation and capability.
This activity is a negative regulator of PAI-1 and PAI-2.
Therefore, an imbalance between the u-PA and PAIs
contributes to the degradation or deposition of ECM
[10,11]. Thus, anti-migration or anti-invasion caused by
a u-PA imbalance with mediated suppression may be a. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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shown that u-PA also influences the development of in-
flammatory, immune, coagulation and fibrinolytic re-
sponses [12]. In the metastasis process, u-PA initiates
the activation of ECM-degrading enzymes, allowing
tumor cells to invade the basement membrane and
enter circulation [5,11,13]. Therefore, inhibiting the ex-
pression of u-PA can potentially be used to treat cancer
metastasis.
Terminalia is a genus of large trees of the flowering
plant family combretaceae. This genus includes approxi-
mately 100 species distributed in tropical and subtrop-
ical regions of Asia, Africa, and Australia. The leaves,
bark, and fruit, of Terminalia catappa have been used as
a folk medicine in several Asian countries for the treat-
ment of dermatitis and as antipyretics. In addition, re-
searchers have identified anticancer compounds in TCE
extract, including some flavonoids and hydrolyzable tan-
nins such as punicalagin, punicalin, etc. Therefore, TCE
has antioxidative, anti-inflammatory, anti-carcinogenesis,
and hepatoprotective effects [14-16]. Our previous study
has shown that TCE inhibits MMP-9 expression in HCC
cells, producing an anti-invasion and anti-migration effect
[3]. However, the molecular mechanisms of u-PA in HCC
metastasis remain unclear. Researchers are increasingly
focusing on u-PA-mediated cancer metastasis [17-21].
For example, Lu et al. reported that ILF3 promotes breast
tumorigenicity by maintaining sustained u-PA expression
in breast cancer cells [17]. He et al. showed that DJ-1 was
correlated with tumor invasion and worse outcome in pan-
creatic ductal adenocarcinoma [18]. They also found that
these effects were associated with the SRC/extracellular
signal-regulated kinase (ERK)/u-PA pathway [18]. More-
over, the transcription of the u-PA gene is regulated by
upstream sequences, including motifs corresponding to
SP-1 and NF-κB binding sites which act independently
or coordinately to regulate u-PA expression [22].
In clinical, other authors have shown that the deregula-
tion of u-PA- and PAI-1-related signaling in metastases
might be relevant to lymph node–negative breast cancer
tissues [19]. Although only a few studies have investigated
the correlation between u-PA and HCC, Itoh et al. re-
ported that u-PA activity may be the most sensitive factor
affecting HCC invasion, and that this activity may be a
strong predictor of the recurrence of HCC [20]. Zheng
et al. showed that u-PA, u-PAR, and PAI-1 may be related
to the invasion, metastasis, and prognosis of HCC [21].
Moreover, the u-PA targeting by molecular technologies
(ex: antisense RNA or shRNA) [23,24], also in human
HCC xenografts decreases the aggressive behavior of HCC
cells inhibiting their migration and invasion capabilities
[25]. In this study, we attempted to verify the u-PA mo-
lecular pathway of TCE in the TCE-mediated suppression
of HCC metastasis.Methods
Preparation of Terminalia catappa leaf extracts (TCE)
Terminalia catappa leaves were purchased from local
herb stores in Taichung, Taiwan. The Terminalia catappa
ethanol extract (TCE) used in this study was prepared by
an initial condensation followed by lyophilization, as de-
scribed previously [26]. The plant material was identified
at the Department of Biochemistry, Chung Shan Medical
University in Taichung. A voucher specimen is deposited
by Dr. Yih-Shou Hsieh. Briefly, 100 g of air-dried leaves
were boiled at 70°C for 24 h in 500 mL of 50% ethanol.
The extraction procedure was repeated twice. The solvent
was then removed from the combined extract with a vac-
uum rotary evaporator. The filtrate was then lyophilized
and stored at −20°C. The chemical profile of the TCE
was analyzed using high-pressure liquid chromatography
(HPLC)–mass spectrometer, as described previously [26].
For subsequent experiments, the dried TCE powder was
dissolved in 50% dimethyl sulfoxide (DMSO) to achieve
an indicated concentration with the highest concentration
of DMSO being less than 0.1%.
Cell culture and TCE treatment
HCC (Huh7) cells obtained from Food Industry Research
and Development Institute (Hsinchu, Taiwan) were cul-
tured in Dulbecco’s modified Eagle’s medium (Life Tech-
nologies, Grand Island, NY, USA), 10% fetal bovine serum,
2 mM glutamine, 100 U/mL penicillin, 100 μg/mL strepto-
mycin, and 400 ng/mL hydrocortisone. All cell cultures
were maintained at 37°C in a humidified atmosphere of
5% CO2. For TCE treatment, appropriate amounts of
stock solution of TCE were added to the culture medium
to achieve the indicated concentrations. The cells were
then incubated for indicated time periods, and dimethyl
sulfoxide solution without TCE was used as a blank
reagent.
In vitro wound closure
Huh7 cells (1 × 105 cells/well) were plated in 6-well
plates for 24 h, and then wounded by scratching with a
pipette tip. The injured cells were then incubated with
DMEM medium containing 0.5% FBS and treated with
or without TCE (0, 25, 50, 75, and 100 μg/mL) for 0, 12,
or 24 h. The cells were photographed using a phase-
contrast microscope (×100).
Cell invasion and migration assays
Cell invasion and migration were assayed following the
methods described by Yang et al. [27]. After treatment
with TCE (0, 25, 50, 75, and 100 μg/mL) for 24 h, the sur-
viving cells were harvested and seeded in a Boyden cham-
ber (Neuro Probe, Cabin John, MD, USA) at 104 cells/well
in serum-free medium and then incubated for 24 h at
37°C. For invasion assay, 10 μL Matrigel (25 mg/50 mL;
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ate membrane filters with an 8-μm pore size, and the
bottom chamber contained standard medium. Filters
were then air-dried for 5 h in a laminar flow hood. The
invaded cells were fixed with 100% methanol and stained
with 5% Giemsa. Cell numbers were counted under a light
microscope. The migration assay was conducted as
described in a previous study by an invasion assay
with no Matrigel coating [28].
Determination of u-PA by casein zymography
The activities of u-PA in a serum-free conditional medium
were measured using casein zymography protease assays,
as described previously [28]. Briefly, prepared samples
containing 20 μL conditional medium were loaded onto a
precast 8% sodium dodecyl sulfate–polyacrylamide gel
containing 2% casein and 20 μg/mL plasminogen. After
electrophoresis, the gel samples were washed with 2.5%
Triton X-100 and incubated in a reaction buffer (40 mM
Tris–HCl, pH 8.0; 10 mM CaCl2; and 0.01% NaN3) for
12 h at 37°C. The gels were then stained with Coomassie
brilliant blue R-250.
RNA preparation and TaqMan quantitative real-time PCR
Total RNA was isolated from HCC cells using Trizol
(Life Technologies, Grand Island, NY) following the
manufacturer’s instructions. Quantitative real-time PCR
analysis was conducted using Taqman one-step PCR
Master Mix (Applied Biosystems). A 100-ng sample of
cDNA was added to each 25 μl reaction with u-PA or
GAPDH primers and TaqMan probes. Quantitative real-
time PCR assays were conducted in triplicate on a
StepOnePlus sequence detection system. The threshold
was set above the non-template control background and
within the linear phase of the target gene amplification to
calculate the cycle number at which the transcript was
detected.
Preparation of total cell lysates
For total cell lysate preparation, cells were rinsed with
PBS twice and scraped with 0.2 mL of cold RIPA buffer
containing protease inhibitors cocktail, and then vortexed
at 4°C for 10 min. Cell lysates were subjected to centrifu-
gation at 10,000 rpm for 10 min at 4°C, and the insoluble
pellet was discarded [29]. The protein concentration of
total cell lysates and nuclear fraction were determined by
Bradford assay [30].
Western blot analysis
The samples containing 20 μg cell lysates were sepa-
rated in a 10% polyacrylamide gel and transferred onto
a nitrocellulose membrane. Each blot was subsequently
incubated with 5% non-fat milk in Tris-buffered saline
(20 mM Tris, 137 mM NaCl, pH 7.6) for 1 h to blocknon-specific binding. Each blot was then incubated over-
night with specific antibodies for u-PA, PAI-1, β-actin,
unphosphorylated or phosphorylated activated forms of
the corresponding ERK1/2, JNK1/2, p38, and Akt. The
blots were then incubated with a horseradish peroxidase
goat anti-rabbit or anti-mouse IgG for 1 h. Signals were
detected using an enhanced chemiluminescence (ECL)
commercial kit (Amersham Biosciences), and the rela-
tive photographic density was quantitated by scanning
the photographic negatives on a gel documentation and
analysis system (AlphaImager 2000, Alpha Innotech
Corporation, San Leandro, CA, USA).
Transfection and u-PA promoter-driven luciferase assays
Huh7 cells were seeded in 6-well cell culture plates at a
concentration of 5 × 104 cells per well. After 24 h of incu-
bation, pGL3-basic (vector) and u-PA promoter plasmid
were co-transfected with a β-galactosidase expression
vector (pCH110) into cells using Turbofect (Fermentas,
Carlsbad, CA). After 12 h of transfection, cells were
treated with vehicle or TCE (0, 25, 50, 75, and 100 μg/mL)
for 24 h. After the cell lysates were harvested, a luciferase
assay kit was used to determine the luciferase activity.
The value of the luciferase activity was normalized to
transfection efficiency and monitored by β-galactosidase
expression.
Chromatin immunoprecipitation analysis (ChIP)
Chromatin immunoprecipitation analysis was performed as
described previously [31]. First, DNA immunoprecipitated
with anti-NF-κB and anti-SP-1 was purified and extracted
using phenol-chloroform. This immunoprecipitated DNA
was then analyzed by PCR or quantitative PCR with
specific primers.
Statistical analysis
Data are indicated as mean ± SD of three different deter-
minations. For all of the measurements, analysis of vari-
ance followed by Student’s t-test (Sigma-Stat 2.0, Jandel
Scientific, San Rafael, CA, USA) was used to assess the dif-
ferences between control and cells treated with various
concentration of TCE. A difference of P < 0.05 was con-
sidered to be statistically significant and the experiments
were repeated 3 times.
Results
Effects of TCE on the Protein Levels of u-PA and its
Endogenous Inhibitor PAI-1
Huh7 cells were treated with TCE (0, 25, 50, 75, and
100 μg/mL) in a serum-free conditional medium for
24 h and then subjected to casein zymography for the
analysis of u-PA activity. As Figures 1A and 1B show,
TCE treatment may lead to reduced activity of u-PA in a
dose-dependent manner. According to western blotting
Figure 1 Effects of TCE on the Protein Levels of u-PA and its Endogenous Inhibitor PAI-1. (A-B) Huh7 cells were treated with TCE
(0–100 μg/mL) for 24 h and then subjected to casein zymography to analyze the activity of u-PA. (C) Huh7 cells were treated with TCE (0–100 μg/mL)
for 24 h and then subjected to western blotting to determine the protein levels of u-PA and PAI-1. (D) Quantitative results of u-PA and PAI-1
protein levels, which were adjusted with the β-actin protein level. The values in this figure represent the means ± SD of at least 3 independent
experiments. *p < 0.05 as compared with the vehicle group.
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u-PA protein expression (Figure 1C). This result shows
that the migration inhibitory effects of TCE at least par-
tially inhibited u-PA expression. An investigation of the
effects of TCE on the protein expression of the u-PA
endogenous inhibitor (PAI-1) shows that TCE induced
PAI-1 upregulation in a concentration-dependent manner
(Figures 1C and 1D).Effects of TCE in suppressing u-PA expression at a
transcriptional level
The results of mRNA testing, reverse transcription PCR
(RT-PCR), real-time PCR, and promoter reporter assays
revealed the inhibitory effects of TCE on u-PA mRNA
expression in Huh7 cells. The Huh7 cells in this study
were treated with 0, 25, 50, 75, and 100 μg/mL of TCE
for 24 h and were then subjected to RT-PCR and real
time-PCR to analyze mRNA levels. The u-PA mRNA levels
decreased considerably in a concentration-dependent man-
ner after treatment with various concentrations of TCE
(Figures 2A-2C). Figure 2D shows that the luciferase activ-
ities of u-PA were significantly suppressed, as determined
by a luciferase assay kit. These results show that TCE reg-
ulates the expression of u-PA, at least partially, at the tran-
scriptional level.The critical role of SP-1 & NF-κB in TCE -induced
transcriptional inhibition of u-PA in Huh7 cells
A ChIP assay was also performed to investigate the ef-
fects of TCE on NF-κB and SP-1 DNA-binding activ-
ities and confirm the transcription factor involvementin the transcriptional inhibitory effects of TCE on u-PA.
Figures 3A and 3C show the levels of SP-1 & NF-κB in a
nucleus that was immunodetected with NF-κB and SP-1
specific antibodies, respectively. These findings indicate
that TCE might induce the transcriptional inhibition of
u-PA in Huh7 cells by suppressing NF-κB and SP-1
binding activity (Figures 3B and 3D).Effects of TCE on the MAPKs pathway and PI3K/Akt
signaling
To further investigate the mechanisms underlying the
upstream signaling pathways of u-PA, we used western
blotting to evaluate the effects of TCE on the MAPK
and Akt pathways. Western blotting showed that TCE
could reduce the phosphorylation of ERK 1/2 (Figure 4A)
in Huh7 cells. The densitometric analyses of blots com-
pared to the control shows that the treatment of TCE at
50 μg/mL could reduce in phosphorylation of ERK 1/2.
However, the phosphorylation of the p38, JNK1/2, and
Akt pathways remained unaffected (Figures 4B-4D).
Therefore, we suggest that the activation of the Erk1/2
signaling pathway is required for TCE to suppress u-PA.Effects of TCE and ERK1/2 inhibitor (U0126) on u-PA
expression, in vitro wound closure, cell migration, and
invasion in Huh7 cells
To further delineate whether the inhibition of proteinase,
invasion, and migration by TCE occurred through the in-
hibition of the ERK1/2 signaling pathway, we investigated
the effects of a specific inhibitor of the ERK1/2 pathway
(U0126) on Huh7 cells. These results show that combined
Figure 2 Effects of TCE suppression on u-PA expression at a transcriptional level. Huh7 cells were treated with TCE (0, 25, 50, 75, and
100 μg/mL) for 24 h and then subjected to RT-PCR (A, B) and quantitative real-time PCR (C) to analyze the mRNA expression of u-PA. (D) u-PA
promoter reporter assay to analyze the promoter activity of u-PA. Luciferase activity, determined in triplicate, was normalized to β-galactosidase
activity. The values in this figure represent the means ± SD of at least 3 independent experiments. *p < 0.05 as compared with the vehicle group.
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u-PA expression (Figures 5A and 5B). We also observed
a similar trend in the inhibition of Huh7 migration and
invasion with combined treatment (Figures 5C-5E).
Therefore, the inhibition of the ERK1/2 signaling path-
ways may reduce the expression of u-PA and tumor
cell invasion.Figure 3 The critical role of NF-κB and SP-1 in TCE -induced transcrip
TCE 100 μg/mL for 24 h and the nuclear fraction was prepared as describe
association of (A-B) NF-κB and (C-D) SP-1 transcription factors with the u-P
the means ± SD of at least 3 independent experiments. *p < 0.05 as compaDiscussion
Metastasis is the process of a cancer cell breaking away
from its original tumor and invading either the circulatory
system or lymphatic system, which carries it to a new lo-
cation, where it positions itself in a new site [32,33]. Al-
though the process of metastasis of cancer cells involves
multiple steps and various cytophysiological modificationstional inhibition of u-PA in Huh7 cells. Huh7 cells were treated with
d in the Methods Section. This figure shows the ChIP analysis of the
A promoter region in Huh7 cells. The values in this figure represent
red with the vehicle group.
Figure 4 Effects of TCE on the MAPKs pathway and PI3K/Akt signaling. Huh7 cells were cultured in various concentrations of TCE (0, 25, 50,
75, and 100 μg/mL) for 24 h. The cell lysates were then subjected to SDS–PAGE followed by western blots with (A) anti-ERK1/2, (B) anti-JNK,
(C) anti-p38, and (D) anti-Akt (total and phosphorylated) antibodies, as described in the Methods Section. The activities of these proteins were
subsequently quantified by densitometric analyses, with the control being 100% (shown just below the gel data). The values in this figure
represent the means ± SD of at least 3 independent experiments. *p < 0.05 as compared with the vehicle group.
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breakdown caused by a protease is the major step in
tumor invasion or migration [34]. This phenomenon leads
to the disjunction of the intercellular matrix, which pro-
motes cancer cell mobility and eventually leads to metas-
tasis. Among the proteases involved, u-PA plays one of the
most important roles in cancer invasion and metastasis
[9]. The results of this study confirm that TCE has an in-
hibitory effect on metastasis through u-PA in HCC cells.
This finding is similar to our previous research of the
compound norcantharidin and resveratrol, which inhibit
u-PA expression to produce anti-migration potential ef-
fects on HCC cells [4,35].
Doctors around the world, and especially in Asian coun-
tries, have been emphasizing the prevention and treatment
of various chronic diseases through the clinical application
of traditional Chinese medicine. Previous studies on folk
medicine have shown that TCE is an important herbal
food drug that has various biological effects, includingantioxidant, hepatoprotective, and antimetastasis effects,
and the prevention of hepatocyte apoptosis [3,16,36-38].
Our previous study reported that TCE has an inhibitory
effect on metastasis in HCC cells [3], but the anti-
migration pathway of u-PA on HCC cells remains un-
clear. This study shows that TCE treatment significantly
inhibited the migration and invasion capacities of Huh
7 cell lines with low cytotoxicity in vitro through the
down-regulation of metastasis-associated u-PA of the
transcription factors SP-1 and NF-κB.
The mitogen-activated protein kinase (MAPK) family of
serine/threonine kinases includes Jun-N-terminal kinase
(JNK), p38, and ERKs. The mammalian ERK1 and ERK2
(ERK1/2) have more than 80% amino acid identity, and
are copiously present in all tissues [14,39,40]. Alterations
of the ERK pathway are well documented in human HCC
cells. The phosphorylated ERK levels are significantly
increased in most human HCC samples [1,41]. The
ERK pathway increases the expression levels of matrix
Figure 5 Effects of TCE and ERK1/2 inhibitor (U0126) on u-PA expression, in vitro wound closure, cell migration, and invasion in Huh7
cells. (A-B) Huh7 cells were pretreated with U0126 for 30 min and then incubated in the presence or absence of TCE for 24 h. The cell lysates
were then subjected to SDS–PAGE followed by western blots with anti-u-PA antibodies, as described in the Methods Section. (C-E) Huh7 cells
were pretreated with U0126 for 30 min and then incubated in the presence or absence of TCE for 24 h. The Huh7 cells were then subjected to
in vitro wound closure, cell migration, and invasion assay. The migration and invasion abilities of Huh7 cells were quantified by counting the
number of cells that invaded the underside of the porous polycarbonate, as described in the Methods Section. The values in this figure represent
the means ± SD of at least 3 independent experiments. *p < 0.05 as compared with the vehicle group.
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and tumor cell invasion [1,42,43]. However, research on
the MAPK pathway and its u-PA-mediated anti-migration
effects on HCC cells are rare. The results of this
study, confirm that TCE inhibits the phosphorylation
of the ERK1/2 pathway, leading to a down-regulation
of metastasis-associated u-PA.
The expression of the u-PA gene is chiefly regulated
by activators or inhibitors and cell surface localization at
the transcriptional, posttranscriptional, and protein levels.
Tang et al. reported that the u-PA system plays an import-
ant role in breast cancer growth, invasion, and metastasis,
which may work through the Ras-ERK or p38-MAPKpathways [11]. The u-PA gene is also crucial to the choice
of adjuvant therapies in node-negative breast cancer
because it provides information regarding the relapse
risk and treatment response [11]. Furthermore, Huang
et al. reported that SDF-1 increases SP-1 DNA-binding
activities in colon cancer cell lines. The inhibition of
SP-1 activation blocked the SDF-1-induced expression
and activity of the u-PA promoter [44]. In this study,
we show that TCE inhibits u-PA promoter in Huh7 cells
through SP-1 and NF-κB, suppressing cell invasion and
metastasis.
For evaluation of the inhibitory effect on the invasive-
ness and migration of human Hepatocellular carcinoma
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to 100 μg/mL which had no cytotoxic effect on Huh7 cells
and it is consistent with in vitro studies from other labora-
tories [45]. Moreover, the toxicity of TCE has been re-
ported that an oral administration of 3,000 mg/kg TCE
did not cause any lethality in the single-dose acute toxicity
test and the treatment by 3,000 mg/kg/day for 30 con-
tinuous days did neither alter the body weights nor the
hematological parameters in C57BL/6 mice in the study
[26]. For the in vivo study, the inhibitory effect of TCE
on the growth and metastasis of Lewis lung carcinoma
cells (LLC) in vivo was proven in the previously study
[26]. Therefore, more animal studies and clinical trials
using the concentration range of TCE are needed to fur-
ther justify its clinical value.
Conclusion
This study shows that TCE has an inhibitory effect on
several crucial steps of metastasis, including cell invasion
and migration, by regulating the activities and protein
level of u-PA and its natural inhibitor. We also demon-
strated that TCE effectively inhibits the phosphorylation
of ERK1/2 signaling pathways by downregulating the tran-
scription factors SP-1 and NF-κB DNA binding activities,
leading to u-PA suppression and inhibiting metastasis.
The signal transduction mediators and transcriptional fac-
tors involved in the TCE anti-migration potential effect on
the HCC cells may lead to the development of specific
mediation to inhibit cell metastasis.
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